Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells (Q39545404)

12 September 2017

title

Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells (English)

1 reference

12 September 2017

1 reference

Shuichi Iwahashi

1

1 reference

12 September 2017

Mitsuo Shimada

2

1 reference

12 September 2017

Tohru Utsunomiya

3

1 reference

12 September 2017

Yuji Morine

4

1 reference

12 September 2017

Satoru Imura

5

1 reference

12 September 2017

Tetsuya Ikemoto

6

1 reference

12 September 2017

Hiroki Mori

7

1 reference

12 September 2017

Jun Hanaoka

8

1 reference

12 September 2017

Koji Sugimoto

9

1 reference

12 September 2017

Yu Saito

10

1 reference

12 September 2017

publication date

10 May 2011

1 reference

International Journal of Clinical Oncology

12 September 2017

published in

1 reference

12 September 2017

volume

16

1 reference

12 September 2017

issue

6

1 reference

12 September 2017

page(s)

671-678

1 reference

https://scigraph.springernature.com/pub.10.1007/s10147-011-0246-y

12 September 2017

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Histone deacetylases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Histone deacetylase and DNA methyltransferase in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Role of the histone deacetylase complex in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

The interferons: a biological system with therapeutic potential in viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Role of interferons in the regulation of cell proliferation, differentiation, and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Cytokine therapeutics: lessons from interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

WAF1, a potential mediator of p53 tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Another Tie that Binds the MTA Family to Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Mi-2/NuRD: multiple complexes for many purposes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-011-0246-Y

p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma.

21 January 2018

1 reference

12 December 2020

Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation

1 reference

12 December 2020

WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis

1 reference

12 December 2020

Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.

1 reference

12 December 2020

A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses

1 reference

12 December 2020

Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model

1 reference

12 December 2020

Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice

1 reference

12 December 2020

Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha

1 reference

12 December 2020

Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B

1 reference

12 December 2020

Interferons in malignancy: biological products or biological response modifiers?

1 reference

12 December 2020

Effects of irinotecan and 5-FU combination therapy in gastric cancer--is combination therapy synergic?

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

10.1007/S10147-011-0246-Y

Identifiers

DOI

1 reference

12 September 2017

1 reference